nach oben

PharmacoEconomics

Erschienen in:

01.07.2005 | Review Article

The state of patient-reported outcomes in atrial fibrillation

A review of current measures

verfasst von: Dr Karin Coyne, Mary Kay Margolis, Susan Grandy, Peter Zimetbaum

Erschienen in: PharmacoEconomics | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting approximately 2.2 million people in the US. The presentation of AF ranges from asymptomatic to severely symptomatic. When symptomatic, AF has been shown to have an adverse impact on health-related quality of life (HR-QOL) and to result in increased healthcare costs. The objective of this analysis was to review the current AF literature on patient-reported outcomes (PROs) in order to evaluate the impact of AF on PROs and the applicability of current PRO measures in assessing AF outcomes.

HR-QOL and symptoms were the most frequently assessed PROs; however, the sensitivity of the majority of the questionnaires for detecting subtle change is not known. For highly symptomatic patients, interventional procedures reduce symptoms and improve HR-QOL; however, this is a small cohort of patients with AF. For the most part, PROs are equivalent between pharmacological treatments or are not known for the large percentage of patients treated pharmacologically with antiarrhythmic or rate-controlling drugs.

PRO assessment in AF patients is an area that needs continued development. AF-specific PRO measures are needed to assess the full range of patient symptoms and treatment outcomes. The impact of paroxysmal AF versus permanent AF is not well delineated, and sex and nationality differences are not known. In addition, the impact of AF on daily activities and HR-QOL is not clearly described.

Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6: 522–31PubMedCrossRef

Leidy NK, Rich M, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2 (2): 113–27PubMedCrossRef

Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155 (5): 469–73PubMedCrossRef

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285 (18): 2370–5PubMedCrossRef

Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001; 104 (17): 2118–50PubMed

Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41 (10): 1690–6PubMedCrossRef

Dorian P, Jung W, Newman D, et al. The impairment of healthrelated quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36 (4): 1303–9PubMedCrossRef

Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356 (9244): 1789–94PubMedCrossRef

Moeremans K, Aliot E, de Chilton C, et al. Second line pharmacological management of paroxysmal and persistant atrial fibrillation in France: a cost analysis. Value Health 2000; 3: 407–16PubMedCrossRef

10.

Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158 (3): 229–34PubMedCrossRef

11.

Ware JE, Snow KK, Kosinski MK, et al. SF-36 Health Survey: Manual and Interpretation Guide. Boston (MA): The Health Institute, New England Medical Center, 1993

12.

Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am Heart J 1992; 124 (2): 381–6PubMedCrossRef

13.

Deaton C, Dunbar SB, Moloney M, et al. Patient experiences with atrial fibrillation and treatment with implantable atrial defibrillation therapy. Heart Lung 2003; 32 (5): 291–9PubMedCrossRef

14.

Ganiats TG, Palinkas LA, Kaplan RM. Comparison of Quality of Well-Being scale and Functional Status Index in patients with atrial fibrillation. Med Care 1992; 30 (10): 958–64PubMedCrossRef

15.

Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association. Am Heart J 1998; 135 (5 Pt 1): 819–24PubMedCrossRef

16.

Gehring J, Perz S, Stieber J, et al. Cardiovascular risk factors, ECG abnormalities and quality of life in subjects with atrial fibrillation. Soz Praventivmed 1996; 41 (3): 185–93PubMedCrossRef

17.

Hamer ME, Blumenthal JA, McCarthy EA, et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 1994; 74 (8): 826–9PubMedCrossRef

18.

Howes CJ, Reid MC, Brandt C, et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J Cardiovasc Pharmacol Ther 2001; 6 (1): 23–9PubMedCrossRef

19.

Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000; 86 (7): 764–8PubMedCrossRef

20.

Savelieva I, Paquette M, Dorian P, et al. Quality of life in patients with silent atrial fibrillation. Heart 2001; 85 (2): 216–7PubMedCrossRef

21.

van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J 2001; 22 (3): 247–53PubMedCrossRef

22.

Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997; 79 (2): 145–9PubMedCrossRef

23.

Gronefeld GC, Lilienthal J, Kuck KH, et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 2003; 24 (15): 1430–6PubMedCrossRef

24.

Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2004; 43 (2): 241–7PubMedCrossRef

25.

Hohnloser SH, Kuck KH, Lilienthal J, et al. Rate and rhythm control showed similar symptom improvement in atrial fibrillation. ACP J Club 2001; 135: 14

26.

Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347 (23): 1825–33PubMedCrossRef

27.

Berry C, Stewart S, Payne EM, et al. Electrical cardioversion for atrial fibrillation: outcomes in “real-life” clinical practice. Int J Cardiol 2001; 81 (1): 29–35PubMedCrossRef

28.

Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002; 23 (11): 892–900PubMedCrossRef

29.

Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25 (2): 144–50PubMedCrossRef

30.

Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002; 143 (6: 984–90PubMedCrossRef

31.

Fung JW, Chan SK, Yeung LY, et al. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Fur J Heart Fail 2002; 4 (4): 489–94CrossRef

32.

Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol 2001; 28 (5-6: 446–50PubMedCrossRef

33.

Anselme F, Saoudi N, Poly H, et al. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation 1999; 99 (4): 534–40PubMedCrossRef

34.

Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74 (3): 242–6PubMedCrossRef

35.

Brignole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized controlled study. Circulation 1997; 96 (8): 2617–24PubMedCrossRef

36.

Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998; 98 (10): 953–60PubMedCrossRef

37.

Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94 (7): 1585–91PubMedCrossRef

38.

Duff HJ, Raj SR, Exner DV, et al. Randomized controlled trial of fixed rate versus rate responsive pacing after radiofrequency atrioventricular junction ablation: quality of life, ventricular refractoriness, and paced QT dispersion. J Cardiovasc Electrophysiol 2003; 14 (11): 1163–70PubMedCrossRef

39.

Erdogan A, Carlsson J, Neumann T, et al. Quality-of-life in patients with paroxysmal atrial fibrillation after catheter ablation: results of long-term follow-up. Pacing Clin Electrophysiol 2003; 26 (3): 678–84PubMedCrossRef

40.

Fitzpatrick AP, Kourouyan HD, Sin A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131 (3): 499–507PubMedCrossRef

41.

Goldberg A, Menen M, Mickelsen S, et al. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. J Interv Card Electrophysiol 2003; 8 (1): 59–64PubMedCrossRef

42.

Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1995; 18 (9 Pt 1): 1609–14PubMedCrossRef

43.

Jessurun ER, van Hemet NM, Defauw JJ, et al. A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery. J Cardiovasc Surg (Torino) 2003; 44 (1): 9–18

44.

Kay GN, Bubien RS, Epstein AE, et al. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62 (10 Pt 1): 741–4PubMedCrossRef

45.

Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol 1998; 2 (2): 121–35CrossRef

46.

Larson MS, McDonald K, Young C, et al. Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. Am J Cardiol 1999; 84 (4): 471–3, A9PubMedCrossRef

47.

Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998; 31 (3): 637–44PubMedCrossRef

48.

Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol 1999; 84 (3): 278–83PubMedCrossRef

49.

Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39 (8): 1258–63PubMedCrossRef

50.

Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study. Heart 2001; 85 (2): 171–8PubMedCrossRef

51.

Levy T, Walker S, Rex S, et al. No incremental benefit of multisite atrial pacing compared with right atrial pacing in patients with drug refractory paroxysmal atrial fibrillation. Heart 2001; 85 (1): 48–52PubMedCrossRef

52.

Lonnerholm S, Blomstrom P, Nilsson L, et al. Effects of the maze operation on health-related quality of life in patients with atrial fibrillation. Circulation 2000; 101 (22): 2607–11PubMedCrossRef

53.

Manolis AG, Katsivas AG, Lazaris EE, et al. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Interv Card Electrophysiol 1998; 2 (1): 71–6PubMedCrossRef

54.

Marshall HJ, Harris ZI, Griffith MJ, et al. Atrioventricular nodal ablation and implantation of mode switching dual chamber pacemakers: effective treatment for drug refractory paroxysmal atrial fibrillation. Heart 1998; 79 (6): 543–7PubMed

55.

Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 1996; 78 (12): 1431–3PubMedCrossRef

56.

Natale A, Zimerman L, Tomassoni G, et al. AV node ablation and pacemaker implantation after withdrawal of effective ratecontrol medications for chronic atrial fibrillation: effect on quality of life and exercise performance. Pacing Clin Electrophysiol 1999; 22 (11): 1634–9PubMedCrossRef

57.

Newman DM, Dorian P, Paquette M, et al. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J 2003; 145 (5): 841–6PubMedCrossRef

58.

Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42 (2): 185–97PubMedCrossRef

59.

Simpson CS, Yee R, Lee JK, et al. Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J 2001; 142 (2): 294–300PubMedCrossRef

60.

Spurrell P, Mitchell A, Kamalvand K, et al. Quality of life after use of the patient activated atrial defibrillator. Int J Clin Pract 2003; 57 (1): 30–4PubMed

61.

Stambler BS, Ellenbogen K, Zhang X, et al. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14 (11): 1180–6PubMedCrossRef

62.

Tada H, Naito S, Kurosaki K, et al. Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. Cite J 2003; 67 (10): 861–5

63.

Twidale N, Manda V, Nave K, et al. Predictors of outcome after radiofrequency catheter ablation of the atrioventricular node for atrial fibrillation and congestive heart failure. Am Heart J 1998; 136 (4 Pt 1): 647–57PubMedCrossRef

64.

Twidale N, McDonald T, Nave K, et al. Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol 1998; 21 (4 Pt 1): 641–51PubMedCrossRef

65.

Weerasooriya R, Davis M, Powell A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41 (10): 1697–702PubMedCrossRef

66.

The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. Am J Cardiol 1997; 79 (9): 1198–202

67.

Fitts SM, Hill MR, Mehra R, et al. Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators. J Interv Card Electrophysiol 1998; 2 (2): 139–44PubMedCrossRef

68.

Roy D, Talajic M, Thibault B, et al. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Am J Cardiol 1997; 80 (4): 464–8PubMedCrossRef

69.

Engelmann MD, Pehrson S. Quality of life in nonpharmacologic treatment of atrial fibrillation. Eur Heart J 2003; 24 (15): 1387–400PubMedCrossRef

Titel: The state of patient-reported outcomes in atrial fibrillation
A review of current measures
verfasst von: Dr Karin Coyne
Mary Kay Margolis
Susan Grandy
Peter Zimetbaum
Publikationsdatum: 01.07.2005
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 7/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523070-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2005

Discounting health effects in pharmacoeconomic evaluations

Evaluating health-related quality-of-life studies in paediatric populations

Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information?

Price differentiation and transparency in the global pharmaceutical marketplace

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK